K. Reeves

发表

Comment and Reply: A double-blind study evaluating the long-term safety of varenicline for smoking cessation

J. Spangler, C. Billing, Clare B. Billing, 2008, Current medical research and opinion.

Varenicline: new treatment with efficacy in smoking cessation.

V. Reus, H. Rollema, R. Obach, 2007, Drugs of today.

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

J. Britton, C. Oncken, C. Billing, 2008, Thorax.

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

N. Rigotti, D. Jorenby, J. T. Hays, 2006, JAMA.

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.

S. Tonstad, P. Hajek, P. Tønnesen, 2006, JAMA.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

S. Rennard, D. Gonzales, C. Oncken, 2006, JAMA.

Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial

S. Potkin, D. Daniel, D. Zimbroff, 1999, Neuropsychopharmacology.

Long-term fatty fish consumption and renal cell carcinoma incidence in women.

R. Anziano, S. Rennard, D. Gonzales, 2006, JAMA.

A comparison of rapid-acting intramuscular (IM) ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation

K. Reeves, E. Harrigan, R. Swift, 1998, European Psychiatry.

Intramuscular ziprasidone 10 mg and 20 mg in patients with psychosis and acute agitation

K. Reeves, E. Harrigan, R. Swift, 1998, European Psychiatry.

A randomized, double-blind comparison of rapid-acting, intramuscular ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation

K. Reeves, E. Harrigan, R. Swift, 1998, European Neuropsychopharmacology.

A double-blind study evaluating the long-term safety of varenicline for smoking cessation*

C. Billing, J. Gong, K. Reeves, 2007, Current medical research and opinion.

Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial

David Gonzales, Jason Gong, Stephen I. Rennard, 2006 .

Human Abuse Liability of the Smoking Cessation Drug Varenicline in Smokers and Nonsmokers

E. Sellers, M. Stolar, E. Sellers, 2008, Clinical pharmacology and therapeutics.

Comment: Oral Varenicline for Smoking Cessation

S. Rennard, D. Jorenby, D. Gonzales, 2007, The Annals of Pharmacotherapy.

Book Review: Emily Monosson (ed.), Motherhood, the Elephant in the Laboratory. New York: Cornell University Press, 2008. xi + 219 pp. (hbk)

K. Reeves, 2011 .

Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial

Jason Gong, Douglas E. Jorenby, N. Rigotti, 2006 .

Pulmonary puzzle

J. Britton, C. Oncken, H. Aubin, 2008, Thorax.

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.

R. Anziano, S. Rennard, D. Gonzales, 2006, Archives of internal medicine.

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

S. Potkin, D. Daniel, K. Reeves, 2001, Psychopharmacology.

P-22-9 The efficacy and safety of two fixed doses of ziprasidone in schizophrenia

K. Reeves, 1996, European Neuropsychopharmacology.

A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition

R. Anziano, N. Cutler, T. Shiovitz, 2004, Journal of clinical psychopharmacology.

Chemical restraint: An idea whose time has gone

W. H. Anderson, K. Reeves, 2004, Administration and Policy in Mental Health and Mental Health Services Research.

Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.

T. Ishibashi, Y. Fujimoto, K. Reeves, 2007, Clinical therapeutics.

The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers : a randomized controlled trial

R. Niaura, D. Jorenby, F. Leone, 2008 .

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.

J. Zajecka, M. Lesem, K. Reeves, 2001, The Journal of clinical psychiatry.

Ziprasidone in the Short-Term Treatment of Patients with Schizoaffective Disorder: Results from Two Double-Blind, Placebo-Controlled, Multicenter Studies

P. Keck, K. Reeves, E. Harrigan, 2001, Journal of clinical psychopharmacology.

The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial

D. Jorenby, F. Leone, R. Niaura, 2008, Current medical research and opinion.

Efficacy of Varenicline, an (cid:1) 4 (cid:2) 2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial

N. Rigotti, D. Jorenby, C. Billing, 2006 .

Efficacy of Varenicline , an 4 2 Nicotinic Acetylcholine Receptor Partial Agonist , vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial

Jason Gong, Douglas E. Jorenby, N. Rigotti, 2006 .

Intramuscular (IM) ziprasidone: A novel treatment for the short-term management of agitated psychotic patients

D. Daniel, J. Lucey, J. V. Lucey, 2000, Schizophrenia Research.

Smoking Cessation With Varenicline, a Selective α4β2 Nicotinic Receptor Partial Agonist: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up

R. Anziano, S. Rennard, D. Gonzales, 2006 .

Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.

R. Anziano, D. Gonzales, C. Oncken, 2006, Archives of internal medicine.